Sorafenib Tablet, Film Coated
Product Images NDC 0480-5425

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Sorafenib (NDC 0480-5425). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Teva Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1 (Image 1)

Chemical structure of the active ingredient Sorafenib, displaying its molecular arrangement and functional groups as part of the drug's formulation.*

FDA Label Image

2 (Image 2)

A Kaplan-Meier survival curve chart comparing survival probability (%) over months from randomization between Sorafenib and Placebo groups. The chart shows survival percentages, median survival times (10.7 months for Sorafenib, 7.9 months for Placebo), hazard ratio (0.69), and p-value (0.00058). Below is a patient risk table listing the number of patients at risk at different time points for each group.*

FDA Label Image

Figure 2 (Image 3)

A Kaplan-Meier curve depicting progression-free survival probability over days from randomization comparing Sorafenib and placebo. Sorafenib group shows higher survival probability with a median of 167 days versus 84 days for placebo. The hazard ratio is 0.44 with a p-value less than 0.000001, indicating statistical significance.*

FDA Label Image

Figure 3 (Image 4)

A Kaplan-Meier survival curve comparing progression-free survival between Sorafenib (N=207) and placebo (N=210) over a period of 30 months. The y-axis represents the proportion of progression-free survival, and the x-axis shows the duration in months. Below the graph is a table of patients at risk for each group at various time points.*

FDA Label Image

1 (Image 5)

Sorafenib Tablets USP 200 mg film-coated tablets label by Teva Pharmaceuticals, Inc. The label shows the product name, strength, dosage form, 120 tablet count, NDC 0480-5425, and includes a serialization coding area. It also states the tablets contain 200 mg of sorafenib tosylate equivalent to 274 mg sorafenib and are for oral use.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.